SCHEDULE: Luther King Capital Management and J. Luther King Jr. Increase Stake in scPharmaceuticals to Over 6%

Luther King Capital Management Corporation and J. Luther King, Jr. have reported increased beneficial ownership in scPharmaceuticals Inc., holding 6.7% and 7.0% of common stock respectively, as of June 30, 2025.

Summary

• Luther King Capital Management Corporation (LKCM) beneficially owns 3,541,170 shares of scPharmaceuticals Inc. Common Stock, representing 6.7% of the class.
• J. Luther King, Jr. beneficially owns 3,669,170 shares of scPharmaceuticals Inc. Common Stock, representing 7.0% of the class.
• Both reporting persons hold sole voting and sole dispositive power over their respective shares.
• The filing is an Amendment No. 6 to Schedule 13G, indicating a change in beneficial ownership.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of scPharmaceuticals Inc.

Sentiment

Score: 7

Explanation: The increased beneficial ownership by a reputable investment firm and individual suggests a positive outlook on the company's value and future performance, indicating confidence.

Positives

• Increased beneficial ownership by an investment adviser and a prominent individual investor may signal confidence in scPharmaceuticals Inc.'s future prospects.
• The filing explicitly states that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control, which can be viewed positively by current management and shareholders.

Future Outlook

NA

Industry Context

This filing indicates a significant stake held by a notable investment firm and its principal in scPharmaceuticals Inc., a company operating in the pharmaceutical sector. Such an increase in institutional ownership can reflect a positive long-term view on the company's drug pipeline, market position, or overall strategic direction within the competitive pharmaceutical industry.

Stakeholder Impact

• Shareholders: Increased institutional ownership may be viewed positively, potentially signaling confidence in the company and attracting further investment.
• Management: The statement that the shares are not held for the purpose of changing or influencing control provides stability and reduces concerns about activist investor intervention.

Key Dates

Recommendation

Keywords

scPharmaceuticals Inc., Common Stock, Schedule 13G, Beneficial Ownership, Luther King Capital Management Corporation, J. Luther King Jr., SEC Filing, Investment Adviser, Institutional Ownership